Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the gynecologic oncology group

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1895-1902

  Bookman, M A ^a   McGuire III, W P ^a   Kilpatrick, D ^a   Keenan, E ^a   Hogan, W M ^a   Johnson, S W ^a   O'Dwyer, P ^a   Rowinsky, E ^a   Gallion, H H ^a   Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 8944233362     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1895     Document Type: Article

References (24)

1. Advanced Ovarian Cancer Trialist Group: Chemotherapy in advanced ovarian cancer; An overview of randomized clinical trials. Br Med J 303:884-893, 1991
2. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1978
3. Kaye SB, Lewis CR, Paul J, et al: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
4. Calvert AH, Newell DR, Gunbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
5. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diammine-dichloroplatinum (II) analogue di-amminecyclobutane-dicarboxy-latoplatinum. Cancer Res 45:6502-6506, 1985
6. Taylor AE, Wiltshaw E, Gore ME, et al: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12:2066-2070, 1994
7. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:707-717, 1992
8. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992
9. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced epithelial neoplasms. Ann Intern Med 111:273-279, 1989
10. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
11. Weiss R, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
12. Thigpen T, Blessing J, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
13. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
14. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
15. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
16. Rowinsky ET, Gibert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
17. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
18. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:605, 1973
19. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1986
20. Schilder RJ, LaCreta FP, Perez RP, et al: Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54:709-717, 1994
21. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
22. Egorin MJ: Further refinement of carboplatin dosing. J Natl Cancer Inst 87:555-557, 1995
23. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995
24. Vermerken RJ, ten Bokkel Huinink WW, Hucink EU, et al: Carboplatin vs cisplatin. Ann Oncol 4:41-48, 1993 (suppl 3)